Search - tctmd.com

Displaying 1 - 20 of 125

Sort: Relevancy | Date

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

News Conference News ACC 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

April 02, 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

News Conference News ACC 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE

News Conference News TCT 2025

Mechanical Thrombectomy Outshines Anticoagulation Alone in STORM-PE

October 26, 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

News Conference News TCT 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

October 25, 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

News Conference News SCAI 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

May 07, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

News Conference News TCT 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

November 04, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

October 28, 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

News Conference News ESC 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

September 03, 2024

Essentials for 3D-ICE in Structural Interventions Explored in Position Statement

News Conference News NY Valves 2024

Essentials for 3D-ICE in Structural Interventions Explored in Position Statement

June 06, 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

May 06, 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.